BR112022008652A2 - Anticorpos biespecíficos hla-a2/wt1 x cd3, uso de um anticorpo biespecífico, método para tratar câncer em um indivíduo, kit e invenção - Google Patents
Anticorpos biespecíficos hla-a2/wt1 x cd3, uso de um anticorpo biespecífico, método para tratar câncer em um indivíduo, kit e invençãoInfo
- Publication number
- BR112022008652A2 BR112022008652A2 BR112022008652A BR112022008652A BR112022008652A2 BR 112022008652 A2 BR112022008652 A2 BR 112022008652A2 BR 112022008652 A BR112022008652 A BR 112022008652A BR 112022008652 A BR112022008652 A BR 112022008652A BR 112022008652 A2 BR112022008652 A2 BR 112022008652A2
- Authority
- BR
- Brazil
- Prior art keywords
- hla
- bispecific
- kit
- individual
- treat cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 4
- 102000025850 HLA-A2 Antigen Human genes 0.000 title abstract 3
- 108010074032 HLA-A2 Antigen Proteins 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 abstract 1
- 229960004942 lenalidomide Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
ANTICORPOS BIESPECÍFICOS HLA-A2/WT1 X CD3, USO DE UM ANTICORPO BIESPECÍFICO, MÉTODO PARA TRATAR CÂNCER EM UM INDIVÍDUO, KIT E INVENÇÃO. A presente invenção refere-se ao tratamento de câncer, em particular ao tratamento de câncer usando um anticorpo biespecífico HLA-A2/WT1 x CD3 e lenalidomida.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19207090 | 2019-11-05 | ||
PCT/EP2020/080763 WO2021089513A1 (en) | 2019-11-05 | 2020-11-03 | Treatment of cancer using a hla-a2/wt1 x cd3 bispecific antibody and lenalidomide |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022008652A2 true BR112022008652A2 (pt) | 2022-07-19 |
Family
ID=68468600
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022008652A BR112022008652A2 (pt) | 2019-11-05 | 2020-11-03 | Anticorpos biespecíficos hla-a2/wt1 x cd3, uso de um anticorpo biespecífico, método para tratar câncer em um indivíduo, kit e invenção |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220275093A1 (pt) |
EP (1) | EP4054716A1 (pt) |
JP (1) | JP2023501276A (pt) |
KR (1) | KR20220093323A (pt) |
CN (1) | CN115003384A (pt) |
AU (1) | AU2020381349A1 (pt) |
BR (1) | BR112022008652A2 (pt) |
CA (1) | CA3155308A1 (pt) |
IL (1) | IL292103A (pt) |
MX (1) | MX2022005238A (pt) |
TW (1) | TW202132341A (pt) |
WO (1) | WO2021089513A1 (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN118201962A (zh) * | 2021-11-01 | 2024-06-14 | 豪夫迈·罗氏有限公司 | 使用HLA-A2/WT1xCD3双特异性抗体和4-1BB(CD137)激动剂治疗癌症 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE102631T1 (de) | 1988-11-11 | 1994-03-15 | Medical Res Council | Klonierung von immunglobulin sequenzen aus den variabelen domaenen. |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
EP0625200B1 (en) | 1992-02-06 | 2005-05-11 | Chiron Corporation | Biosynthetic binding protein for cancer marker |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
CA3041183A1 (en) * | 2016-11-02 | 2018-05-11 | Engmab Sarl | Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma |
MA51302A (fr) | 2017-12-21 | 2021-03-31 | Hoffmann La Roche | Anticorps se liant à hla-a2/wt1 |
-
2020
- 2020-11-03 CA CA3155308A patent/CA3155308A1/en active Pending
- 2020-11-03 EP EP20797512.9A patent/EP4054716A1/en active Pending
- 2020-11-03 MX MX2022005238A patent/MX2022005238A/es unknown
- 2020-11-03 JP JP2022525603A patent/JP2023501276A/ja active Pending
- 2020-11-03 KR KR1020227015509A patent/KR20220093323A/ko unknown
- 2020-11-03 AU AU2020381349A patent/AU2020381349A1/en active Pending
- 2020-11-03 WO PCT/EP2020/080763 patent/WO2021089513A1/en unknown
- 2020-11-03 BR BR112022008652A patent/BR112022008652A2/pt not_active Application Discontinuation
- 2020-11-03 CN CN202080076682.8A patent/CN115003384A/zh active Pending
- 2020-11-04 TW TW109138371A patent/TW202132341A/zh unknown
-
2022
- 2022-04-10 IL IL292103A patent/IL292103A/en unknown
- 2022-05-05 US US17/662,117 patent/US20220275093A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
TW202132341A (zh) | 2021-09-01 |
JP2023501276A (ja) | 2023-01-18 |
AU2020381349A1 (en) | 2022-04-28 |
IL292103A (en) | 2022-06-01 |
EP4054716A1 (en) | 2022-09-14 |
US20220275093A1 (en) | 2022-09-01 |
WO2021089513A1 (en) | 2021-05-14 |
CA3155308A1 (en) | 2021-05-14 |
CN115003384A (zh) | 2022-09-02 |
KR20220093323A (ko) | 2022-07-05 |
MX2022005238A (es) | 2022-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2023000907A1 (es) | Anticuerpos de unión a gprc5d | |
CY1124384T1 (el) | Κατασκευες διπλοειδικων αντισωματων που δεσμευονται σε egfrviii και cd3 | |
CO2019012210A2 (es) | Anticuerpos anti-trem2 y métodos para utilizarlos | |
DOP2020000128A (es) | Anticuerpos anti-trem2 y métodos relacionados | |
UY37083A (es) | Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso | |
MD3328888T2 (ro) | Anticorpi anti-PSMA, molecule de legare a antigenelor bispecifice care leagă PSMA și CD3 și utilizările acestora | |
ECSP20024555A (es) | Anticuerpos especificos para cd47 y pd-l1 | |
MX2019004621A (es) | Anticuerpo biespecifico contra bcma y cd3 y un farmaco inmunologico para uso combinado en el tratamiento del mieloma multiple. | |
DOP2019000253A (es) | Anticuerpos anti-ilt4 y fragmentos de unión a antígeno | |
NZ750132A (en) | Bispecific trivalent antibodies binding to claudin6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases | |
EA201890390A8 (ru) | БИСПЕЦИФИЧЕСКИЕ КОНСТРУКТЫ АНТИТЕЛ, СВЯЗЫВАЮЩИЕ EGFRvIII И CD3 | |
PE20210289A1 (es) | Anti-cd25 para el agotamiento de celulas tumorales especificas | |
CL2021001506A1 (es) | Anticuerpos que se unen a cd3 | |
CO2020013089A2 (es) | Anticuerpos contra mica y/o micb y sus usos | |
CL2021000909A1 (es) | Anticuerpos estabilizadores de trem2 | |
BR112022004995A2 (pt) | Anticorpos biespecíficos contra ceacam5 e cd3 | |
BR112021012631A2 (pt) | Anticorpos anti-ctla4 e métodos de uso dos mesmos | |
CL2020001629A1 (es) | Anticuerpos de unión a hla-a2/wt1. | |
BR112022022800A2 (pt) | Métodos para tratamento de mieloma múltiplo | |
CL2021000146A1 (es) | Anticuerpos humanizados contra psma | |
BR112021020532A2 (pt) | Métodos para tratamento de câncer de próstata com um anticorpo anti-psma/cd3 | |
MX2022001947A (es) | Anticuerpos que se unen a las proteinas lrp5 y metodos de uso. | |
BR112022008652A2 (pt) | Anticorpos biespecíficos hla-a2/wt1 x cd3, uso de um anticorpo biespecífico, método para tratar câncer em um indivíduo, kit e invenção | |
MX2021012765A (es) | Metodos para tratar el cancer renal con un anticuerpo anti-psma/cd3. | |
EA201992522A1 (ru) | КОМБИНАЦИЯ БИСПЕЦИФИЧЕСКОГО АНТИТЕЛА К ErbB-2/ErbB-3 С ЭНДОКРИННОЙ ТЕРАПИЕЙ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |